Cytokeratins and lung carcinomas

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Cytokeratins (CK) are increasingly utilized as tumor markers in various carcinomas.
• Their role in lung cancer diagnosis, including distinguishing primary from secondary tumors, histological typing, and prognosis, is under investigation.
• Previous studies yielded inconclusive results, necessitating further research.

Purpose of the Study:

• To investigate the expression of cytokeratins (CK7, CK10/13, CK18, CK19, CK20) in lung cancer.
• To analyze cytokeratin immunophenotypes in relation to histological characteristics, TNM stages, and patient survival.
• To determine the utility of these CKs in differentiating lung carcinoma subtypes.

Main Methods:

• Analysis of 72 surgically resected lung specimens: 31 adenocarcinomas, 30 squamous cell carcinomas, and 11 neuroendocrine carcinomas.
• Immunohistochemical staining for CK7, CK10/13, CK18, CK19, and CK20.
• Comparison of cytokeratin expression patterns with tumor histology, TNM staging, and patient survival data.

Main Results:

• CK7, CK10/13, and CK18 effectively distinguish lung adenocarcinomas (CK7+, CK10/13-, CK18+) from squamous cell carcinomas (CK7-, CK10/13+, CK18-).
• CK19 showed high expression in both adenocarcinoma (90.3%) and squamous cell carcinoma (86.7%), while CK20 expression was low (9.7% and 3.3%, respectively).
• Neuroendocrine tumors were generally non-reactive, except for abundant CK18 expression in carcinoid tumors. Prognostic significance of CK7 and CK18 in squamous cell carcinoma was suggested but not confirmed.

Conclusions:

• Specific cytokeratin profiles (CK7, CK10/13, CK18) are valuable for differentiating lung adenocarcinoma from squamous cell carcinoma.
• CK19 is a common marker for both major lung cancer types, whereas CK20 is rare.
• CK18 is expressed in neuroendocrine tumors, particularly carcinoids, aiding in their identification.